Prevent concomitant utilization of tucatinib with CYP3A substrates, wherever negligible focus variations may perhaps produce serious or life-threatening toxicities. If unavoidable, cut down CYP3A substrate dose In keeping with product or service labeling. If you skip a dose, just take it when you